Form 4: Incyte EVP Barry Flannelly Reports Acquisition of Common Stock Following Performance Share Vesting
SEC Form 4
EVP and General Manager of Incyte, Barry P. Flannelly, reports the acquisition of common stock related to performance shares, with vesting contingent on continued service and retirement provisions.
Summary
- Barry P. Flannelly, EVP & General Manager US at Incyte Corp, reported changes in beneficial ownership of Incyte common stock on April 1, 2025.
- The report details the acquisition of 11,159 shares of common stock related to performance shares earned based on Opzelura performance criteria.
- These shares will vest on November 30, 2025, despite Dr. Flannelly's retirement on July 31, 2025, due to retirement provisions.
- Additionally, 14,976 shares were acquired related to performance shares earned based on development, revenue, and market-based performance goals set in January 2022.
- These shares will vest on July 2, 2025, contingent on continued service.
- Following these transactions, Flannelly beneficially owns 59,702 shares, including 59,689 unvested shares from previously reported RSUs and earned performance shares.
Sentiment
Score: 7
Explanation: The sentiment is neutral to slightly positive. The vesting of performance shares suggests that performance targets were met, which is a positive indicator. However, it's a routine disclosure and doesn't necessarily imply significant changes in the company's outlook.
Positives
- The vesting of performance shares indicates that performance criteria related to Opzelura, development, revenue, and market-based goals were met.
- The retirement provisions allowing vesting even after retirement could be seen as a positive benefit for executives.
Future Outlook
The document does not contain specific forward-looking statements, but the vesting of performance shares suggests confidence in the company's performance.
Industry Context
Executive compensation and stock ownership are common disclosures in the pharmaceutical industry, reflecting alignment of management interests with shareholder value.
Comparison to Industry Standards
- Stock awards are a typical component of executive compensation packages in the biotechnology and pharmaceutical industries.
- Companies like Amgen, Gilead Sciences, and Regeneron also utilize performance-based equity awards to incentivize executives.
- The vesting schedules and performance metrics described are consistent with industry practices.
Management Changes
| Role | Previous Person | New Person | Effective Date | Reason |
|---|---|---|---|---|
| EVP & General Manager US | Barry P. Flannelly | TBD | July 31, 2025 | Retirement |
Stakeholder Impact
- Shareholders may view the vesting of performance shares positively, as it indicates that management is incentivized to achieve company goals.
- Employees may see this as a positive sign of company performance and stability.
Key Dates
| Date | Description |
|---|---|
| July 2, 2022 | Grant date of performance share award agreement. |
| January 2022 | Issuers Compensation Committee determined performance goals. |
| April 1, 2025 | Date of transaction and determination of satisfied performance criteria. |
| July 2, 2025 | Vesting date for 14,976 performance shares, subject to continued service. |
| July 31, 2025 | Dr. Flannelly's retirement date. |
| November 30, 2025 | Vesting date for 11,159 performance shares related to Opzelura performance. |
Keywords
Incyte, Flannelly, performance shares, beneficial ownership, common stock, Opzelura, vesting, retirement
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.